MAPT and Alzheimer disease: Aberrant levels of Aβ and tau proteins in cerebrospinal fluid (CSF) and blood have been evaluated as biomarkers for AD diagnosis [7, 8], specifically, increased levels of total and hyperphosphorylated tau proteins, and decreased levels of Aβ in CSF.